Pharvaris
Nieves Crespo Alcarria is an experienced professional in toxicology and safety pharmacology. With a background in veterinary science and biochemistry, Alcarria has held various roles in different companies, focusing on toxicological development of new drugs, outsourcing toxicity studies, and authoring regulatory documents. Alcarria's expertise extends to being a study director for toxicology and having experience in animal welfare.
This person is not in any offices
Pharvaris
2 followers
Pharvaris is a preclinical stage company focused on bringing an oral bradykinin B2 receptor antagonist to patients for use as an alternative to injected therapies for hereditary angioedema (HAE) and other B2 receptor-mediated indications. The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.